Eligibility and radiologic assessment in adjuvant clinical trials in bladder cancer Review
| Authors: | Apolo, A. B.; Milowsky, M. I.; Kim, L.; Inman, B. A.; Kamat, A. M.; Steinberg, G.; Bagheri, M.; Krishnasamy, V. P.; Marko, J.; Dinney, C. P.; Bangs, R.; Sweis, R. F.; Maher, V. E.; Ibrahim, A.; Liu, K.; Werntz, R.; Cross, F.; Beaver, J. A.; Singh, H.; Pazdur, R.; Blumenthal, G. M.; Lerner, S. P.; Bajorin, D. F.; Rosenberg, J. E.; Agrawal, S. |
| Review Title: | Eligibility and radiologic assessment in adjuvant clinical trials in bladder cancer |
| Abstract: | Objective: To harmonize eligibility criteria and radiographic disease assessments in clinical trials of adjuvant therapy for muscle-invasive bladder cancer (MIBC). Methods: National experts in bladder cancer clinical trial research, including medical and urologic oncologists, radiologists, biostatisticians, and patient advocates, convened at a public workshop on November 28, 2017, to discuss eligibility, radiographic entry criteria, and assessment of disease recurrence in adjuvant clinical trials in patients with MIBC. Results: The key workshop conclusions for adjuvant MIBC clinical trials included the following points: (1) patients with urothelial carcinoma with divergent histologic differentiation should be allowed to enroll; (2) neoadjuvant chemotherapy is defined as at least 3 cycles of neoadjuvant cisplatin-based combination chemotherapy; (3) patients with muscle-invasive, upper-Tract urothelial carcinoma should be included in adjuvant trials of MIBC; (4) patients with severe renal insufficiency can enroll into trials using agents that are not renally excreted; (5) patients with microscopic surgical margins can be included; (6) patients should undergo a standard bilateral lymph node dissection prior to enrollment; (7) computed tomographic (CT) imaging should be performed within 4 weeks prior to enrollment. For patients with renal insufficiency who cannot undergo CT imaging with contrast, noncontrast chest CT and magnetic resonance imaging of the abdomen and pelvis with gadolinium should be done; (8) biopsy of indeterminate lesions to evaluate for malignant disease should be done when feasible; (9) a uniform approach to evaluate indeterminate radiographic lesions when biopsy is not feasible should be included in any trial design; (10) a uniform approach to determining the date of recurrence is important in interpreting adjuvant trial results; and (11) new high-grade, upper-Tract primary tumors and new MIBC tumors should be considered recurrence events. Conclusions and Relevance: A uniform approach to eligibility criteria, definitions of no evidence of disease, and definitions of disease recurrence may lead to more consistent interpretations of adjuvant trial results in MIBC. © 2019 American Medical Association. All rights reserved. |
| Keywords: | cancer recurrence; cisplatin; nuclear magnetic resonance imaging; lymph node metastasis; lymph node dissection; pelvis lymph node; cancer grading; computer assisted tomography; multiple cycle treatment; kidney failure; cell differentiation; histology; disease severity; radiologist; contrast enhancement; neoadjuvant chemotherapy; transitional cell carcinoma; medical expert; workshop; oncologist; muscle invasive bladder cancer; cystography; human; article; disease assessment |
| Journal Title: | JAMA Oncology |
| Volume: | 5 |
| Issue: | 12 |
| ISSN: | 2374-2437 |
| Publisher: | American Medical Association |
| Date Published: | 2019-12-01 |
| Start Page: | 1790 |
| End Page: | 1798 |
| Language: | English |
| DOI: | 10.1001/jamaoncol.2019.4114 |
| PUBMED: | 31670753 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work